BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol. 2012;56:686-695. [PMID: 21971559 DOI: 10.1016/j.jhep.2011.07.031] [Cited by in Crossref: 114] [Cited by in F6Publishing: 112] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Lu Y, Zhang C, Huang D, Wu W, Zhang Y, Shen J, Cai Y, Chen W, Yao W. FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition. Int J Oncol 2018;52:1455-64. [PMID: 29568938 DOI: 10.3892/ijo.2018.4327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
2 Zamboni CG, Kozielski KL, Vaughan HJ, Nakata MM, Kim J, Higgins LJ, Pomper MG, Green JJ. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release 2017;263:18-28. [PMID: 28351668 DOI: 10.1016/j.jconrel.2017.03.384] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
3 Vogl TJ, Lee C. Doxorubicin -eluting beads in the treatment of liver carcinoma. Expert Opin Pharmacother 2014;15:115-20. [PMID: 24215628 DOI: 10.1517/14656566.2014.855719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Liu XW, Cai TY, Zhu H, Cao J, Su Y, Hu YZ, He QJ, Yang B. Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma. Autophagy 2014;10:111-22. [PMID: 24220190 DOI: 10.4161/auto.26838] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
5 Strebel BM. Sorafenib prolongs survival, but what happens to the symptoms? Journal of Hepatology 2012;57:222-3. [DOI: 10.1016/j.jhep.2012.01.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Huang Y, Cai Y, Huang R, Zheng X. Rosmarinic Acid Combined with Adriamycin Induces Apoptosis by Triggering Mitochondria-Mediated Signaling Pathway in HepG2 and Bel-7402 Cells. Med Sci Monit 2018;24:7898-908. [PMID: 30391993 DOI: 10.12659/MSM.910673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Zhou Y, Chen E, Tang Y, Mao J, Shen J, Zheng X, Xie S, Zhang S, Wu Y, Liu H, Zhi X, Ma T, Ni H, Chen J, Chai K, Chen W. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis 2019;10:843. [PMID: 31695022 DOI: 10.1038/s41419-019-2053-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
8 Saito M, Takano T, Nishimura T, Kohara M, Tsukiyama-Kohara K. 3β-hydroxysterol δ24-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy. PLoS One 2015;10:e0124197. [PMID: 25875901 DOI: 10.1371/journal.pone.0124197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
9 Savier E, Simon-Gracia L, Charlotte F, Tuffery P, Teesalu T, Scatton O, Rebollo A. Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. Pharmaceutics 2021;13:1631. [PMID: 34683924 DOI: 10.3390/pharmaceutics13101631] [Reference Citation Analysis]
10 Sun R, Dong C, Li R, Chu H, Liu J, Hao D, Zhang L, Zhao B, Wang L, Zhang Y. Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. Proteomics Clin Appl 2020;14:e1900080. [PMID: 32067389 DOI: 10.1002/prca.201900080] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhao X, Chen Q, Li Y, Tang H, Liu W, Yang X. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 2015;93:27-36. [PMID: 25770771 DOI: 10.1016/j.ejpb.2015.03.003] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 13.1] [Reference Citation Analysis]
12 Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget 2013;4:1496-506. [PMID: 24036604 DOI: 10.18632/oncotarget.1236] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
13 Gabrielson A, Tesfaye AA, Marshall JL, Pishvaian MJ, Smaglo B, Jha R, Dorsch-Vogel K, Wang H, He AR. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2015;76:1073-9. [PMID: 26449224 DOI: 10.1007/s00280-015-2852-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
14 Wang F, Ye X, Zhai D, Dai W, Wu Y, Chen J, Chen W. Curcumin-loaded nanostructured lipid carrier induced apoptosis in human HepG2 cells through activation of the DR5/caspase-mediated extrinsic apoptosis pathway. Acta Pharm 2020;70:227-37. [PMID: 31955141 DOI: 10.2478/acph-2020-0003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
15 Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241 [PMID: 24415877 DOI: 10.3748/wjg.v20.i1.235] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
16 Alipour M, Bigdeli M, Aligholi H, Rasoulian B, Khaksarian M. Sustained release of silibinin‐loaded chitosan nanoparticle induced apoptosis in glioma cells. J Biomed Mater Res 2020;108:458-69. [DOI: 10.1002/jbm.a.36827] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
17 Wang C, Gao W, Feng M, Pastan I, Ho M. Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. Oncotarget 2017;8:32450-60. [PMID: 27419635 DOI: 10.18632/oncotarget.10592] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
18 Valero V 3rd, Pawlik TM, Anders RA. Emerging role of Hpo signaling and YAP in hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:69-78. [PMID: 27508196 DOI: 10.2147/JHC.S48505] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
19 Pazgan-Simon M, Serafinska S, Janocha-Litwin J, Simon K, Zuwala-Jagiello J. Diagnostic challenges in primary hepatocellular carcinoma: case reports and review of the literature. Case Rep Oncol Med 2015;2015:878763. [PMID: 25922775 DOI: 10.1155/2015/878763] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Zhou QM, Lu YF, Zhou JP, Yang XY, Wang XJ, Yu JN, Du YZ, Yu RS. Self-amplification of oxidative stress with tumour microenvironment-activatable iron-doped nanoplatform for targeting hepatocellular carcinoma synergistic cascade therapy and diagnosis. J Nanobiotechnology 2021;19:361. [PMID: 34749740 DOI: 10.1186/s12951-021-01102-0] [Reference Citation Analysis]
21 Dong C, Zhao B, Long F, Liu Y, Liu Z, Li S, Yang X, Sun D, Wang H, Liu Q, Liang R, Li Y, Gao Z, Shao S, Miao QR, Wang L. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein. Oncotarget 2016;7:8850-65. [PMID: 26840457 DOI: 10.18632/oncotarget.7091] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
22 Peng WX, Xiong EM, Ge L, Wan YY, Zhang CL, Du FY, Xu M, Bhat RA, Jin J, Gong AH. Egr-1 promotes hypoxia-induced autophagy to enhance chemo-resistance of hepatocellular carcinoma cells. Exp Cell Res 2016;340:62-70. [PMID: 26708617 DOI: 10.1016/j.yexcr.2015.12.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
23 Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, Gatalica Z, Reddy SK, Yee NS, Abou-Alfa GK. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. J Surg Oncol. 2016;113:55-61. [PMID: 26661118 DOI: 10.1002/jso.24086] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
24 Chen S, Xia X. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met. J Cell Physiol. 2019;epub ahead of print. [PMID: 30937906 DOI: 10.1002/jcp.27567] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
25 Kunter I, Erdal E, Nart D, Yilmaz F, Karademir S, Sagol O, Atabey N. Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma. Oncol Rep 2014;31:573-80. [PMID: 24337632 DOI: 10.3892/or.2013.2932] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
26 Hsu HT, Chi CW. Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:127-35. [PMID: 27508182 DOI: 10.2147/JHC.S48512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
27 Shing K, Kwok G, Chiu J, Cheung TT, Yau T. Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? Ann Transl Med 2020;8:1695. [PMID: 33490207 DOI: 10.21037/atm-2020-130] [Reference Citation Analysis]
28 Contreras L, Rodríguez-gil A, Muntané J, de la Cruz J. Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells. Cancers 2022;14:1204. [DOI: 10.3390/cancers14051204] [Reference Citation Analysis]
29 Zhang B, Jiang J, Wu P, Zou J, Le J, Lin J, Li C, Luo B, Zhang Y, Huang R, Shao J. A smart dual-drug nanosystem based on co-assembly of plant and food-derived natural products for synergistic HCC immunotherapy. Acta Pharm Sin B 2021;11:246-57. [PMID: 33532190 DOI: 10.1016/j.apsb.2020.07.026] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Wang F, Wu Z. Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma. Exp Ther Med 2018;15:5371-6. [PMID: 29844803 DOI: 10.3892/etm.2018.6086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
31 Herath NI, Devun F, Herbette A, Lienafa M, Chouteau P, Sun J, Dutreix M, Denys A. Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models. Eur Radiol 2017;27:4435-44. [DOI: 10.1007/s00330-017-4792-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
32 Wilkins LR, Brautigan DL, Wu H, Yarmohammadi H, Kubicka E, Serbulea V, Leitinger N, Liu W, Haaga JR. Cinnamic Acid Derivatives Enhance the Efficacy of Transarterial Embolization in a Rat Model of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2017;40:430-7. [PMID: 27872984 DOI: 10.1007/s00270-016-1515-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
33 Kwak M, Yu SJ, Yoon J, Lee S, Lee S, Lee J, Kim YJ, Lee H, Kim CY. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. J Cancer Res Clin Oncol 2015;141:2037-45. [DOI: 10.1007/s00432-015-1990-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
34 Sreekumar R, Emaduddin M, Al-Saihati H, Moutasim K, Chan J, Spampinato M, Bhome R, Yuen HM, Mescoli C, Vitale A, Cillo U, Rugge M, Primrose J, Hilal MA, Thirdborough S, Tulchinsky E, Thomas G, Mirnezami A, Sayan AE. Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC. Cell Death Dis 2019;10:703. [PMID: 31543517 DOI: 10.1038/s41419-019-1885-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
35 He X, Yu J, Xiong L, Liu Y, Fan L, Li Y, Chen B, Chen J, Xu X. Exosomes derived from liver cancer cells reprogram biological behaviors of LO2 cells by transferring Linc-ROR. Gene 2019;719:144044. [DOI: 10.1016/j.gene.2019.144044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
36 Abdelmoneem MA, Mahmoud M, Zaky A, Helmy MW, Sallam M, Fang JY, Elkhodairy KA, Elzoghby AO. Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma. J Control Release 2018;287:78-93. [PMID: 30138716 DOI: 10.1016/j.jconrel.2018.08.026] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
37 Lu L, Zhang D, Xu Y, Bai G, Lv Y, Liang J. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1. Biomed Pharmacother 2018;104:613-21. [PMID: 29803174 DOI: 10.1016/j.biopha.2018.05.087] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
38 Li WT, Zou AE, Honda CO, Zheng H, Wang XQ, Kisseleva T, Chang EY, Ongkeko WM. Etiology-Specific Analysis of Hepatocellular Carcinoma Transcriptome Reveals Genetic Dysregulation in Pathways Implicated in Immunotherapy Efficacy. Cancers (Basel) 2019;11:E1273. [PMID: 31480259 DOI: 10.3390/cancers11091273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 O’grady S, Lawless MW. Liver Cancer (Hepatocellular Carcinoma). Epigenetic Cancer Therapy. Elsevier; 2015. pp. 269-88. [DOI: 10.1016/b978-0-12-800206-3.00012-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Xiang Y, Huang W, Huang C, Long J, Zhou Y, Liu Y, Tang S, He DX, Tan XW, Wei H, Yu CY. Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy In Vitro and In Vivo. Mol Pharm 2020;17:3223-35. [PMID: 32658485 DOI: 10.1021/acs.molpharmaceut.0c00327] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Goldstein R, Yu D, Gillmore R, Thirlwell C, O'Donoghue P, Mayer A, Meyer T. Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. Future Oncol 2014;10:2007-14. [PMID: 25209630 DOI: 10.2217/fon.14.108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
42 Xiong Q, Bai Y, Shi R, Wang J, Xu W, Zhang M, Song T. Preferentially released miR-122 from cyclodextrin-based star copolymer nanoparticle enhances hepatoma chemotherapy by apoptosis induction and cytotoxics efflux inhibition. Bioact Mater 2021;6:3744-55. [PMID: 33898875 DOI: 10.1016/j.bioactmat.2021.03.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108:1252-1259. [PMID: 23449352 DOI: 10.1038/bjc.2013.85] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 8.9] [Reference Citation Analysis]
44 Gai X, Zhou P, Xu M, Liu Z, Zheng X, Liu Q. Hyperactivation of IL-6/STAT3 pathway leaded to the poor prognosis of post-TACE HCCs by HIF-1α/SNAI1 axis-induced epithelial to mesenchymal transition. J Cancer 2020;11:570-82. [PMID: 31942180 DOI: 10.7150/jca.35631] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
45 Zhou J, Zhang X, Tang H, Yu J, Zu X, Xie Z, Yang X, Hu J, Tan F, Li Q, Lei X. Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in autophagy-induced hepatocellular carcinoma. Clin Chim Acta 2020;506:1-8. [PMID: 32109431 DOI: 10.1016/j.cca.2020.02.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Yue J, Wang Z, Shao D, Chang Z, Hu R, Li L, Luo S, Dong W. Cancer cell membrane-modified biodegradable mesoporous silica nanocarriers for berberine therapy of liver cancer. RSC Adv 2018;8:40288-97. [DOI: 10.1039/c8ra07574c] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 4.5] [Reference Citation Analysis]
47 Azad I, Jafri A, Khan T, Akhter Y, Arshad M, Hassan F, Ahmad N, Khan AR, Nasibullah M. Evaluation of pyrrole-2,3-dicarboxylate derivatives: Synthesis, DFT analysis, molecular docking, virtual screening and in vitro anti-hepatic cancer study. Journal of Molecular Structure 2019;1176:314-34. [DOI: 10.1016/j.molstruc.2018.08.049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
48 Lin Q, Wu Z, Yue X, Yu X, Wang Z, Song X, Xu L, He Y, Ge Y, Tan S, Wang T, Song H, Yuan D, Gong Y, Gao L, Liang X, Ma C. ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation. EBioMedicine 2020;53:102676. [PMID: 32114388 DOI: 10.1016/j.ebiom.2020.102676] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
49 Fako V, Yu Z, Henrich CJ, Ransom T, Budhu AS, Wang XW. Inhibition of wnt/β-catenin Signaling in Hepatocellular Carcinoma by an Antipsychotic Drug Pimozide. Int J Biol Sci 2016;12:768-75. [PMID: 27313491 DOI: 10.7150/ijbs.14718] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
50 Niu LL, Cheng CL, Li MY, Yang SL, Hu BG, Chong CCN, Chan SL, Ren J, Chen GG, Lai PBS. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. Cell Death Dis 2018;9:852. [PMID: 30154433 DOI: 10.1038/s41419-018-0926-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
51 Duan J, Chen W, Xie J, Zhang M, Nie R, Liang H, Mei J, Han K, Xiang Z, Wang F, Teng K, Chen R, Deng M, Yin Y, Zhang N, Xie D, Cai M. A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01537-5] [Reference Citation Analysis]
52 Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res. 2013;19:6678-6685. [PMID: 24030702 DOI: 10.1158/1078-0432.ccr-13-1721] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
53 Cui J, Liu J, Fan L, Zhu Y, Zhou B, Wang Y, Hua W, Wei W, Sun G. A zinc finger family protein, ZNF263, promotes hepatocellular carcinoma resistance to apoptosis via activation of ER stress-dependent autophagy. Transl Oncol 2020;13:100851. [PMID: 32898766 DOI: 10.1016/j.tranon.2020.100851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Chang HL, Chen HA, Bamodu OA, Lee KF, Tzeng YM, Lee WH, Tsai JT. Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. Toxicol In Vitro 2018;51:74-82. [PMID: 29698666 DOI: 10.1016/j.tiv.2018.04.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
55 Fasiku VO, Aderibigbe BA, Sadiku ER, Lemmer Y, Owonubi SJ, Ray SS, Mukwevho E. Polyethylene glycol–gum acacia-based multidrug delivery system for controlled delivery of anticancer drugs. Polym Bull 2019;76:5011-37. [DOI: 10.1007/s00289-018-2642-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
56 Zhang H, Yu QL, Meng L, Huang H, Liu H, Zhang N, Liu N, Yang J, Zhang YZ, Huang Q. TAZ-regulated expression of IL-8 is involved in chemoresistance of hepatocellular carcinoma cells. Arch Biochem Biophys 2020;693:108571. [PMID: 32898567 DOI: 10.1016/j.abb.2020.108571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Al-Madboly LA, El-Deeb NM, Kabbash A, Nael MA, Kenawy AM, Ragab AE. Purification, Characterization, Identification, and Anticancer Activity of a Circular Bacteriocin From Enterococcus thailandicus. Front Bioeng Biotechnol 2020;8:450. [PMID: 32656185 DOI: 10.3389/fbioe.2020.00450] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Zhang X, Xu P, Ni W, Fan H, Xu J, Chen Y, Huang W, Lu S, Liang L, Liu J, Chen B, Shi W. Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma. Pathol Res Pract 2016;212:162-70. [PMID: 26804244 DOI: 10.1016/j.prp.2016.01.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
59 Singh A, Shafi S, Upadhyay T, Najmi AK, Kohli K, Pottoo FH. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment. Curr Top Med Chem 2020;20:1839-54. [PMID: 32579503 DOI: 10.2174/1568026620666200624161801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kelley RK. Brivanib and FOLFOX in Hepatocellular Carcinoma: Finding the Common Themes Among Negative Trials. JCO 2013;31:3483-6. [DOI: 10.1200/jco.2013.49.7941] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
61 Wang Z, Tan J, McConville C, Kannappan V, Tawari PE, Brown J, Ding J, Armesilla AL, Irache JM, Mei QB, Tan Y, Liu Y, Jiang W, Bian XW, Wang W. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine 2017;13:641-57. [PMID: 27521693 DOI: 10.1016/j.nano.2016.08.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
62 Baitello ME, Tenani GD, Ferreira RF, Nogueira V, Pinhel MA, da Silva RC, da Silva RF, Fucuta PD, de Godoy MF, Souza DR. VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2016;2016:9607054. [PMID: 27660750 DOI: 10.1155/2016/9607054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
63 Gan G, Shi Z, Liu D, Zhang S, Zhu H, Wang Y, Mi J. 3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness. Cell Death Discov 2021;7:173. [PMID: 34230478 DOI: 10.1038/s41420-021-00561-6] [Reference Citation Analysis]
64 Pratama MY, Pascut D, Massi MN, Tiribelli C. The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Ann Transl Med 2019;7:577. [PMID: 31807558 DOI: 10.21037/atm.2019.09.142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
65 Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L, Liu W, Li B, Meng S, Xiong W, Mi J. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases. Theranostics 2021;11:6006-18. [PMID: 33897895 DOI: 10.7150/thno.59841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Ma H, Yue X, Gao L, Liang X, Yan W, Zhang Z, Shan H, Zhang H, Spear BT, Ma C. ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA. Oncotarget 2015;6:1049-63. [PMID: 25473899 DOI: 10.18632/oncotarget.2832] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
67 Bi QC, Tang JJ, Zhao J, Lv YF, Deng ZQ, Chen H, Xu YH, Xie CS, Liang QR, Luo RG, Tang Q. Sevelamer arsenite nanoparticle as a Pi-responsive drug carrier and embolic agent for chemoembolization. Drug Deliv 2022;29:1447-56. [PMID: 35532152 DOI: 10.1080/10717544.2022.2072541] [Reference Citation Analysis]
68 Zhou HH, Chen L, Liang HF, Li GZ, Zhang BX, Chen XP. Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT. Int J Mol Sci 2016;17:E610. [PMID: 27110775 DOI: 10.3390/ijms17040610] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
69 Centelles JJ. General aspects of colorectal cancer. ISRN Oncol. 2012;2012:139268. [PMID: 23209942 DOI: 10.5402/2012/139268] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
70 Li D, Zhang B, Hu C. Oxaliplatin inhibits proliferation and migration of human hepatocellular carcinoma cells via GAS7C and the N-WASP/FAK/F-actin pathway. Acta Biochim Biophys Sin (Shanghai) 2017;49:581-7. [PMID: 28475688 DOI: 10.1093/abbs/gmx046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
71 You ML, Chen YJ, Chong QY, Wu MM, Pandey V, Chen RM, Liu L, Ma L, Wu ZS, Zhu T, Lobie PE. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent. Oncotarget 2017;8:39323-44. [PMID: 28445151 DOI: 10.18632/oncotarget.16950] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
72 Zhao B, Ma Y, Xu Z, Wang J, Wang F, Wang D, Pan S, Wu Y, Pan H, Xu D, Liu L, Jiang H. Hydroxytyrosol, a natural molecule from olive oil, suppresses the growth of human hepatocellular carcinoma cells via inactivating AKT and nuclear factor-kappa B pathways. Cancer Letters 2014;347:79-87. [DOI: 10.1016/j.canlet.2014.01.028] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
73 Sokolowski KM, Balamurugan M, Kunnimalaiyaan S, Wilson J, Gamblin TC, Kunnimalaiyaan M. Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy. Am J Surg 2016;211:755-60. [PMID: 26850133 DOI: 10.1016/j.amjsurg.2015.11.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
74 Shu G, Zhang L, Jiang S, Cheng Z, Wang G, Huang X, Yang X. Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction. Oncotarget 2016;7:40285-96. [PMID: 27244888 DOI: 10.18632/oncotarget.9603] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
75 Wu C, Yang M, Wang C. Quercetin-3-O-glucuronide inhibits doxorubicin resistance by reducing endoplasmic reticulum stress in hepatocellular carcinoma cells. Journal of Functional Foods 2019;54:301-9. [DOI: 10.1016/j.jff.2019.01.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
76 Zhang T, Li G, Li S, Wang Z, He D, Wang Y, Zhang J, Li J, Bai Z, Zhang Q, Liu B, Zhao Q, Liu Y, Zhang H. Asialoglycoprotein receptor targeted micelles containing carborane clusters for effective boron neutron capture therapy of hepatocellular carcinoma. Colloids and Surfaces B: Biointerfaces 2019;182:110397. [DOI: 10.1016/j.colsurfb.2019.110397] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
77 Chen CC, Chen CY, Ueng SH, Hsueh C, Yeh CT, Ho JY, Chou LF, Wang TH. Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair. Cell Death Dis 2018;9:543. [PMID: 29749376 DOI: 10.1038/s41419-018-0575-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
78 Qin Y, Wang C, Jiang Y, Liu T, Yang J, Lin R, Zhang T. Phosphorylcholine oligomer-grafted graphene oxide for tumor-targeting doxorubicin delivery. RSC Adv 2017;7:41675-85. [DOI: 10.1039/c7ra08287h] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
79 Hayashi A, Shibahara J, Misumi K, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M. Histologic Assessment of Intratumoral Lymphoplasmacytic Infiltration Is Useful in Predicting Prognosis of Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0155744. [PMID: 27195977 DOI: 10.1371/journal.pone.0155744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
80 Li M, Cui ZG, Zakki SA, Feng Q, Sun L, Feril LB Jr, Inadera H. Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. J Cell Physiol 2019;234:20249-65. [PMID: 30993729 DOI: 10.1002/jcp.28625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
81 Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2019; 25(24): 2977-2989 [PMID: 31293335 DOI: 10.3748/wjg.v25.i24.2977] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 53] [Article Influence: 19.7] [Reference Citation Analysis]
82 Qin S, Gong X. Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. Hepat Oncol 2016;3:71-81. [PMID: 30191027 DOI: 10.2217/hep.15.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Yang S, Wang M, Yang L, Li Y, Ma Y, Peng X, Li X, Li B, Jin H, Li H. MicroRNA-375 Targets ATG14 to Inhibit Autophagy and Sensitize Hepatocellular Carcinoma Cells to Sorafenib. Onco Targets Ther 2020;13:3557-70. [PMID: 32431510 DOI: 10.2147/OTT.S247655] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
84 Feltrin FDS, Agner T, Sayer C, Lona LMF. Curcumin encapsulation in functional PLGA nanoparticles: A promising strategy for cancer therapies. Adv Colloid Interface Sci 2021;300:102582. [PMID: 34953375 DOI: 10.1016/j.cis.2021.102582] [Reference Citation Analysis]
85 Duan Y, Chen J, Yang Y, Qu Z, Lu Y, Sun D. LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a. Biosci Rep 2020;40:BSR20201627. [PMID: 32700738 DOI: 10.1042/BSR20201627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
86 Lai WL, Hung WY, Ching YP. The tumor suppressor, TAX1BP2, is a novel substrate of ATM kinase. Oncogene 2014;33:5303-9. [PMID: 24240686 DOI: 10.1038/onc.2013.481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Wu Q, Liu HO, Liu YD, Liu WS, Pan D, Zhang WJ, Yang L, Fu Q, Xu JJ, Gu JX. Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity. J Biol Chem. 2015;290:1170-1185. [PMID: 25422324 DOI: 10.1074/jbc.m114.601203] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
88 Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma – A novel therapeutic approach. Journal of Hepatology 2015;63:102-13. [DOI: 10.1016/j.jhep.2015.01.031] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
89 Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One 2014;9:e115565. [PMID: 25531114 DOI: 10.1371/journal.pone.0115565] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
90 Takahashi K, Yan IK, Kogure T, Haga H, Patel T. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio. 2014;4:458-467. [PMID: 24918061 DOI: 10.1016/j.fob.2014.04.007] [Cited by in Crossref: 258] [Cited by in F6Publishing: 257] [Article Influence: 32.3] [Reference Citation Analysis]
91 Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou Y, Chen C, Yang Y, Miele L, Sarkar FH. Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget. 2013;4:1999-2009. [PMID: 24158561 DOI: 10.18632/oncotarget.1471] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
92 Cao H, Wang Y, He X, Zhang Z, Yin Q, Chen Y, Yu H, Huang Y, Chen L, Xu M, Gu W, Li Y. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm 2015;12:922-31. [PMID: 25622075 DOI: 10.1021/mp500755j] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 8.1] [Reference Citation Analysis]
93 Yu T, Tong L, Ao Y, Zhang G, Liu Y, Zhang H. NIR triggered PLGA coated Au-TiO2 core loaded CPT-11 nanoparticles for human papillary thyroid carcinoma therapy. Drug Deliv 2020;27:855-63. [PMID: 32515668 DOI: 10.1080/10717544.2020.1775723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
94 Shi Y, Yu Y, Wang Z, Wang H, Bieerkehazhi S, Zhao Y, Suzuk L, Zhang H. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells. Oncotarget 2016;7:73697-710. [PMID: 27655642 DOI: 10.18632/oncotarget.12048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
95 Wu F, Chen WJ, Yan L, Tan GQ, Li WT, Zhu XJ, Ge XC, Liu JW, Wang BL. Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathway. Cancer Med 2016;5:370-85. [PMID: 26714930 DOI: 10.1002/cam4.588] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
96 Zhao X, Chen Q, Liu W, Li Y, Tang H, Liu X, Yang X. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int J Nanomedicine 2015;10:257-70. [PMID: 25565818 DOI: 10.2147/IJN.S73322] [Cited by in Crossref: 13] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
97 Chen XP, Li Y, Zhang Y, Li GW. Formulation, Characterization And Evaluation Of Curcumin- Loaded PLGA- TPGS Nanoparticles For Liver Cancer Treatment. Drug Des Devel Ther 2019;13:3569-78. [PMID: 31802845 DOI: 10.2147/DDDT.S211748] [Cited by in Crossref: 10] [Article Influence: 3.3] [Reference Citation Analysis]
98 Li S, Peng F, Ning Y, Jiang P, Peng J, Ding X, Zhang J, Jiang T, Xiang S. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma. J Cell Biochem. 2020;121:2543-2558. [PMID: 31696971 DOI: 10.1002/jcb.29477] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
99 Wang Z, Wang YS, Chang ZM, Li L, Zhang Y, Lu MM, Zheng X, Li M, Shao D, Li J, Chen L, Dong WF. Berberine-loaded Janus nanocarriers for magnetic field-enhanced therapy against hepatocellular carcinoma. Chem Biol Drug Des 2017;89:464-9. [PMID: 27618577 DOI: 10.1111/cbdd.12866] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
100 Pan C, Wang X, Shi K, Zheng Y, Li J, Chen Y, Jin L, Pan Z. MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism. PLoS One 2016;11:e0152090. [PMID: 27138141 DOI: 10.1371/journal.pone.0152090] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
101 Chen D, Xie F, Sun D, Yin C, Gao J, Zhong Y. Nanomedicine-Mediated Combination Drug Therapy in Tumor. PHARMSCI 2017;4:1-10. [DOI: 10.2174/1874844901704010001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
102 Rai V, Abdo J, Alsuwaidan AN, Agrawal S, Sharma P, Agrawal DK. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Mol Cell Biochem 2018;437:13-36. [DOI: 10.1007/s11010-017-3092-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
103 Hu H, Yang L, Li L, Zeng C. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis. Biochem Biophys Res Commun. 2018;503:2400-2406. [PMID: 29966655 DOI: 10.1016/j.bbrc.2018.06.168] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
104 Kumar P, Singh AK, Raj V, Rai A, Maity S, Rawat A, Kumar U, Kumar D, Prakash A, Guleria A, Saha S. 6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid attenuates heptatocellular carcinoma in rats with NMR-based metabolic perturbations. Future Sci OA 2017;3:FSO202. [PMID: 28884001 DOI: 10.4155/fsoa-2017-0008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
105 Zhang S, Li G, Zhao Y, Liu G, Wang Y, Ma X, Li D, Wu Y, Lu J. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. PLoS One 2012;7:e51461. [PMID: 23240027 DOI: 10.1371/journal.pone.0051461] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
106 Zhao R, Li T, Zheng G, Jiang K, Fan L, Shao J. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials 2017;143:1-16. [DOI: 10.1016/j.biomaterials.2017.07.030] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 17.2] [Reference Citation Analysis]
107 Li J, Yang Z, Tuo B. Role of OCT1 in hepatocellular carcinoma. Onco Targets Ther 2019;12:6013-22. [PMID: 31413596 DOI: 10.2147/OTT.S212088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
108 Guo W, Tan HY, Wang N, Wang X, Feng Y. Deciphering hepatocellular carcinoma through metabolomics: from biomarker discovery to therapy evaluation. Cancer Manag Res 2018;10:715-34. [PMID: 29692630 DOI: 10.2147/CMAR.S156837] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
109 You Y, Zhu F, Li Z, Zhang L, Xie Y, Chinnathambi A, Alahmadi TA, Lu B. Phyllanthin prevents diethylnitrosamine (DEN) induced liver carcinogenesis in rats and induces apoptotic cell death in HepG2 cells. Biomed Pharmacother 2021;137:111335. [PMID: 33581648 DOI: 10.1016/j.biopha.2021.111335] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Liu Y, Chen L, Yuan H, Guo S, Wu G. LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells. Onco Targets Ther 2020;13:1145-57. [PMID: 32103983 DOI: 10.2147/OTT.S229957] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
111 Alanazi SA, Harisa GI, Badran MM, Haq N, Radwan AA, Kumar A, Shakeel F, Alanazi FK. Cholesterol-Conjugate as a New Strategy to Improve the Cytotoxic Effect of 5-Fluorouracil on Liver Cancer: Impact of Liposomal Composition. CDD 2020;17:898-910. [DOI: 10.2174/1567201817666200211095452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
112 Huang D, Dai H, Tang K, Chen B, Zhu H, Chen D, Li N, Wang Y, Liu C, Huang Y, Yang J, Zhang C, Lin R, He W. A versatile UCST-type composite microsphere for image-guided chemoembolization and photothermal therapy against liver cancer. Nanoscale 2020;12:20002-15. [PMID: 32996987 DOI: 10.1039/d0nr04592f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Dubbelboer IR, Pavlovic N, Heindryckx F, Sjögren E, Lennernäs H. Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. Cancers (Basel) 2019;11:E1024. [PMID: 31330834 DOI: 10.3390/cancers11071024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
114 Gani SA, Muhammad SA, Kura AU, Barahuie F, Hussein MZ, Fakurazi S. Effect of protocatechuic acid-layered double hydroxide nanoparticles on diethylnitrosamine/phenobarbital-induced hepatocellular carcinoma in mice. PLoS One 2019;14:e0217009. [PMID: 31141523 DOI: 10.1371/journal.pone.0217009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Xu P, Zhang X, Ni W, Fan H, Xu J, Chen Y, Zhu J, Gu X, Yang L, Ni R, Chen B, Shi W. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma. Dig Dis Sci 2015;60:3351-63. [DOI: 10.1007/s10620-015-3774-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
116 Fu X, Luo RG, Qiu W, Ouyang L, Fan GQ, Liang QR, Tang Q. Sustained release of arsenic trioxide benefits interventional therapy on rabbit VX2 liver tumor. Nanomedicine 2020;24:102118. [PMID: 31678180 DOI: 10.1016/j.nano.2019.102118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Kumar P, Rawat A, Keshari AK, Singh AK, Maity S, De A, Samanta A, Saha S. Antiproliferative effect of isolated isoquinoline alkaloid from Mucuna pruriens seeds in hepatic carcinoma cells. Natural Product Research 2015;30:460-3. [DOI: 10.1080/14786419.2015.1020489] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
118 Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM, Wörns MA, Weinmann A, Galle PR, Zimmermann T. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer 2016;16:94. [PMID: 26872727 DOI: 10.1186/s12885-016-2150-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]